ArticleTranslational oncology2026
FABP4 characterizes metabolic-immune interactions and serves as a prognostic biomarker across gynecologic malignancies: a multi-omics integrative analysis.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gynecological malignancies-including breast, cervical, ovarian, endometrial cancers and uterine sarcoma-pose a serious threat to women's health owing to their high incidence, aggressiveness and frequent recurrence. Fatty acid-binding protein 4 (FABP4) is a key regulator of lipid metabolism and tumor metabolic reprogramming, yet systematic investigations of its role across gynecological malignancies remain scarce. Here, by integrating data from TCGA, GTEx and multiple public repositories, we performed a multi-omics, multi-scale analysis of five gynecological malignancies, encompassing transcriptomics, DNA methylation, copy-number variation (CNV), single-cell RNA sequencing and spatial transcriptomics. FABP4 was markedly downregulated in most gynecological tumors, and its expression correlated significantly with tumor grade, clinical stage and patient prognosis, demonstrating robust diagnostic performance. Survival analyses revealed a tumor-type-dependent prognostic value: high FABP4 expression was associated with poor outcomes in ovarian and cervical cancers, but with favorable prognosis in endometrial cancer. Methylation, CNV and somatic mutation analyses indicated that FABP4 downregulation is significantly associated with promoter hypermethylation, suggesting that epigenetic silencing is a major contributing mechanism. Single-cell and spatial transcriptomic profiling localized FABP4 expression mainly to stromal populations-particularly endothelial cells and fibroblasts-and revealed close associations with the tumor immune microenvironment. Drug sensitivity analyses further identified several small-molecule compounds capable of reversing FABP4 dysregulation-associated transcriptional signatures, targeting key oncogenic pathways including PI3K/mTOR, RTK signaling and the cell cycle. Collectively, this study delineates the expression patterns, molecular mechanisms and microenvironmental functions of FABP4 across gynecological malignancies, providing a foundation for its application as a diagnostic and prognostic biomarker and as a potential therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.